A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Cynthia X Wei(Indiana University Health), Shadia I. Jalal(Indiana University Health), Hirva Mamdani(Wayne State University), Susan M. Perkins(Indiana University School of Medicine), Sandra K. Althouse(Indiana University School of Medicine), Maitri Kalra(LifeBridge Health), Ryan D. Gentzler(University of Virginia Health System)
Cited by 6
Related Papers
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
|Journal of Clinical Oncology|2018|208
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125
A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells
|Cell Reports Medicine|2021|121